CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
vancomycin, magnesium citrate, microbiota +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04132427
NCT04132427Phase 2Completed

Microbiota Transfer Therapy for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

Arizona State University·interventional·Posted Oct 18, 2019·Updated Aug 26, 2024

In Brief

A Phase 2 clinical trial evaluating vancomycin, magnesium citrate, microbiota and placebo vancomycin, real magnesium citrate, placebo microbiota for Pitt Hopkins Syndrome. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt Hopkins Syndrome (PTHS) and gastrointestinal problems similar to Irritable Bowel Syndrome (IBS). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by a bowel cleanse, followed by 12 weeks of Fecal Microbiota (FM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 18, 2019
Enrollment StartSep 30, 2019
Primary CompletionMar 17, 2022
Study CompletionApr 15, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.7 years ago

Interventions

vancomycin, magnesium citrate, microbiotacombination

10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota

placebo vancomycin, real magnesium citrate, placebo microbiotacombination

10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota